Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT II)

Inclusion Criteria: * Patients with metastatic cancer * Patients may have received unlimited lines of prior therapy * Prior to randomization, patients with metastatic disease must have been treated with established standard-of-care therapy, or physicians have determined that such established therapy is not sufficiently efficacious, or patients have declined to receive standard-of-care therapy * The patient has measurable disease * The patient has Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * The patient has biopsy-accessible tumor; for patients who had no prior anticancer therapy and had surgical resection within a year and tumor tissue is immediately available, that tumor will be analyzed and no biopsy will be needed * Absolute neutrophil count \>= 1,000/ul * Platelets \>= 100,000/ul (unless these abnormalities are due to bone marrow involvement) * Total bilirubin level \<= 1.5 x the upper limit of normal (ULN), unless the patient has known Gilbert's disease * Alanine aminotransferase (ALT)/ serum glutamic pyruvic transaminase levels (SGPT) =\< 2.5 X ULN (unless the patient has liver metastases) * Serum creatinine clearance \>= 50 ml/min by the Cockcroft-Gault formula * If the patient has brain metastasis, they must have been stable (treated and/or asymptomatic) and the patient must have been off steroids for at least 2 weeks * The patient has provided signed informed consent * Patients with a previous malignancy (other than the patients' known cancer) …